Immunmodulation in Patients With HHT

Hereditary Haemorrhagic Telangiectasia (HHT) Clinical Trial

Official title:

Immunmodulation in Patients With HHT

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02983253
• Other study ID #: ImmunUHEssen
• Status: Completed
• Start date: June 2016
• Est. completion date: October 2019

Study information

• Verified date: December 2019
• Source: University Hospital, Essen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder. Literature suggests that HHT is often associated with higher frequency of infectious diseases.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Description:

Hereditary haemorrhagic telangiectasia (HHT), also known as Rendu-Osler-Weber syndrome, is an inherited multisystemic disorder with recurrent epistaxis, mucocutaneous telangiectasia and visceral arteriovenous malformations. Literature and the investigators' observation suggest that HHT is often associated with higher frequency of infectious diseases. This might be a hint for a immunocompromised situation.

The purpose of this study is to evaluate a variety of immunologic parameters in the blood serum of HHT patients in comparison to probands.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: October 2019
• Est. primary completion date: October 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• aged 18 or over, HHT

Exclusion Criteria:

• Unable to provide informed consent

Related Conditions & MeSH terms

• Hereditary Haemorrhagic Telangiectasia (HHT)
• Telangiectasia, Hereditary Hemorrhagic
• Telangiectasis

Intervention

Other:
• blood sample
none, only laboratory tests on blood serum

Locations

Country	Name	City	State
Germany	University Hospital Essen	Essen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Essen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Functional properties of leucocytes in patients with HHT		November 2016 - December 2018
Other	Differences in size of leucocytes in patients with HHT		November 2016 - December 2018
Primary	Amounts of leucocytes in patients with HHT		November 2016 - December 2018
Secondary	Differences in distribution of leucocytes in patients with HHT		November 2016 - December 2018